About Us
Founded in 1944, the American Committee for the Weizmann Institute of Science develops philanthropic support for the Weizmann Institute in Israel, and advances its mission of science for the future of humanity.
Jan 04, 2016...
Magnetic resonance images of the prostate gland after treatment with TOOKAD® Soluble. The black regions show the portions of the prostate where cancer was identified and eliminated by the therapy.
REHOVOT, ISRAEL—January 4, 2016—A therapy invented at the Weizmann Institute of Science and clinically developed in collaboration with Steba Biotech (Luxembourg) has been approved by Cofepris, Mexico’s health authority, for the focal treatment of early-stage prostate cancer.
Apr 29, 2019...
TOOKAD® optic fibers illuminate only the cancerous regions, leaving healthy tissue alone
REHOVOT, ISRAEL—April 29, 2019—Steba Biotech, a privately owned company, has, in collaboration with scientists at the Weizmann Institute of Science, conducted extensive research and development on the prostate cancer treatment TOOKAD® – and now has received marketing authorization to make it available in 31 European countries. Following this regulatory approval, the first patients are currently being treated in top Israeli, German, English, and Italian medical centers.
Jul 25, 2019...
BiondVax
A universal flu vaccine is the key to combating the ever-mutating flu virus, but did we ever really stop to think about whether there is a better way?
The flu virus, or influenza, is far more than a week-long inconvenience that pulls us away from our commitments, although that, in and of itself, is pretty annoying. The flu can get deadly fast. According to the World Health Organization, influenza kills up to 650,000 people each year. Read that number again. In the US alone, the flu kills about 12,000 people in mild years, and up to 56,000 people in the more severe years, according to the Center for Disease Control.
https://www.weizmann-usa.org/news-media/feature-stories/keeping-men-healthy-the-weizmann-way/
Jun 07, 2016... Keeping Men Healthy, the Weizmann Way
https://www.weizmann-usa.org/news-media/feature-stories/lighting-the-way-for-a-new-cancer-treatment/
Jul 01, 2006... Research led by Prof. Avigdor Scherz of the Weizmann Institute of Science Department of Plant Sciences and Prof. Yoram Salomon of the Institute’s Department of Biological Regulation, Israel, is coming to fruition in a potential new treatment for prostate cancer. “This therapy requires knowledge of physics, chemistry and biology, as well as scientific methods of the twenty-first century,” Prof. Scherz said during a recent visit to the offices of the American Committee for the Weizmann Institute of Science (ACWIS) in New York.
https://www.weizmann-usa.org/news-media/feature-stories/research-on-aging-at-the-weizmann-institute/
Aug 01, 2012... According to the World Health Organization (WHO), in 1900, the global average life span was 31 years of age. By 2030, in highly developed places such as the U.S., average life expectancy at birth is expected to be around 85. And while wisdom may come with age, so do many unwanted issues, such as poor physical and mental health. In addition, an aging population takes a toll on society: older people are often harder to treat medically; it can be more challenging to get around, either on foot or by driving; and general quality of life may be reduced.
https://www.weizmann-usa.org/news-media/in-the-news/brain-s-immune-system-key-to-reversing-dementia/
Aug 18, 2015...
New research gives hope to those suffering with dementia
Leading neurobiologist Professor Michal Schwartz said the findings were “very exciting” – and showed for the first time that a diseased brain was able to fight the debilitating condition.
Scientists saw a significant drop in the symptoms of dementia when they reduced the cells that prevent the immune system from reacting.
The study by experts at the Weizmann Institute of Science in Israel and published in journal Nature Communications, offers hope of a drug for the disease which affects about 850,000 people in Britain.
https://www.weizmann-usa.org/news-media/feature-stories/teaming-up-to-defeat-prostate-cancer/
May 28, 2015...
Prostate cancer is the second most common type of cancer – and the second leading cause of cancer-related deaths – among American men. According to the Centers for Disease Control and Prevention (CDC), one in six men will be diagnosed with prostate cancer during his lifetime.
Three leading researchers in this field – Prof. Avigdor Scherz of the Department of Plant Sciences at Israel’s Weizmann Institute of Science; Dr. Peter Scardino, Chair of the Department of Surgery at Memorial Sloan Kettering Cancer Center (MSKCC) in New York City; and Dr. Peter Schulam, Chair of the Department of Urology at the Yale School of Medicine, New Haven – agree that safer, more effective detection methods and treatments are needed for the more than 240,000 men diagnosed with prostate cancer each year. Speaking at an event co-sponsored by the New York Region of the American Committee for the Weizmann Institute of Science and the Association of Yale Alumni in Medicine, the researchers described the current state of prostate cancer diagnosis and therapy and discussed their collaboration on a highly promising new treatment.
Jun 06, 2016...
Last month a new treatment was revealed - invented in Israel at the Weizmann Institute - which is making its way to the public. The company leading the commercialization of the technology is Steba Biotech, led by a Jewish father-son team from France who previously owned one of the largest private pharmaceutical companies in the country.
Raphael and Fabrice Harari sold a significant portion of their previous business ventures to fund their vision for Steba; they even rejected, they say, an investment based on a valuation of more than a billion dollars - because of their Zionism.
Sep 07, 2016... Prostate and Ovarian Cancer: What Weizmann is Doing
©2023 American Committee for the Weizmann Institute of Science
